8-K: Amwell Q2 2025: EBITDA Improves, Revenue Guidance Cut

Amwell reported improved Adjusted EBITDA in Q2 2025, driven by strategic initiatives and cost alignment, despite a net loss and a downward revision to full-year revenue guidance.

Summary

• Total Revenue for Q2 2025 was $70.9 million, with subscription revenue at $40.4 million and Amwell Medical Group (AMG) visit revenue at $22.8 million.
• Gross margin for Q2 2025 was 56.1%.
• Net loss for Q2 2025 was ($19.5) million, compared to ($18.4) million in Q1 2025.
• Adjusted EBITDA significantly improved to ($4.7) million in Q2 2025, from ($12.2) million in Q1 2025.
• Total visits in Q2 2025 reached 1.2 million.
• The company added Florida Blue as a new strategic client and announced an extension award from the US Defense Health Agency.
• Full-year 2025 revenue guidance was revised downward to a range of $245 million to $250 million, from the previous guidance of $250 million to $260 million, reflecting the divestiture of Amwell Psychiatric Care.
• Full-year 2025 AMG visits guidance remained unchanged at 1.3 million to 1.35 million.
• Full-year 2025 Adjusted EBITDA guidance was narrowed and improved to a range of ($50) million to ($45) million, from the previous guidance of ($55) million to ($45) million.
• Q3 2025 revenue is projected to be in the range of $53 million to $56 million, with Q3 adjusted EBITDA in the range of ($15) million to ($13) million.
• The company reiterated its objective to achieve positive cash flow from operations in 2026.

Sentiment

Score: 4

Explanation: While Adjusted EBITDA improved significantly and strategic wins were announced, the downward revision of full-year revenue guidance and the sequential decline in Q3 revenue guidance indicate underlying challenges in top-line growth. The continued net loss and cash burn, despite improvements, temper overall sentiment.

Positives

• Adjusted EBITDA showed significant improvement, reaching ($4.7) million in Q2 2025 compared to ($12.2) million in Q1 2025, indicating progress in cost alignment.
• Gross margin remained strong at 56.1% for Q2 2025.
• Secured Florida Blue as a new strategic client, validating the value of the Amwell platform.
• Received an extension award from the US Defense Health Agency, ensuring continued partnership for virtual care delivery.
• Narrowed and improved the full-year 2025 Adjusted EBITDA guidance to ($50) million to ($45) million, reflecting better expected profitability.
• Reiterated the objective to achieve positive cash flow from operations in 2026, providing a clear financial target.

Negatives

• Net loss increased sequentially to ($19.5) million in Q2 2025 from ($18.4) million in Q1 2025.
• Full-year 2025 revenue guidance was revised downward to $245 million-$250 million from $250 million-$260 million, indicating a reduction in expected top-line performance.
• Q3 2025 revenue guidance of $53 million-$56 million suggests a significant sequential decline from Q2 2025 revenue of $70.9 million.

Risks

• Ability to successfully transition clients to Converge without significant attrition.
• Ability to renew and upsell the client base.
• Uncertainty regarding the Defense Health Agency's election to deploy the solution across their entire enterprise.
• Continuation of the DHA relationship beyond July 2026 with comparable financial terms.
• Weak growth and increased volatility in the telehealth market.
• Ability to adapt to rapid technological changes.
• Increased competition from existing and potential new participants in the healthcare industry.
• Changes in healthcare laws, regulations, or trends and the ability to operate in the heavily regulated healthcare industry.
• Ability to comply with federal and state privacy regulations.
• Significant liability that could result from a cybersecurity breach.
• Ability to commence and complete strategic transformation initiatives and the impact of such initiatives.

Future Outlook

The company revised its 2025 revenue guidance downward to $245 million to $250 million, reflecting the divestiture of Amwell Psychiatric Care. However, it narrowed and improved its 2025 Adjusted EBITDA guidance to ($50) million to ($45) million. For Q3 2025, revenue is projected to be $53 million to $56 million, and Adjusted EBITDA is expected to be ($15) million to ($13) million. The company reiterated its objective to achieve positive cash flow from operations in 2026.

Management Comments

• "In Q2, we pursued our strategic initiatives with focus and strong execution. We added Florida Blue, an innovative, large health plan, to our list of strategic clients. We also announced the extension award from the US Defense Health Agency, through which Amwell will continue to enable U.S. Defense Health Agency healthcare teams to deliver connected and seamless in-person and virtual care delivery for the Military Health System. Both provide strong validation of the value of our Amwell platform." Ido Schoenberg, MD, chairman and CEO.
• "We also made significant progress in our revenue quality and cost alignment measures, resulting in another strong quarter of EBITDA improvement, advancing us toward our goal of achieving positive cash flow from operations in 2026." Ido Schoenberg, MD, chairman and CEO.

Industry Context

The telehealth market continues to evolve with increasing demand for virtual care solutions. Amwell's focus on a comprehensive SaaS-based platform for payers and health systems positions it within the enterprise segment of the digital health industry. The addition of a large health plan like Florida Blue and the extension with the US Defense Health Agency indicate continued demand for established, large-scale virtual care infrastructure, despite potential market volatility mentioned as a risk. The divestiture of Amwell Psychiatric Care suggests a strategic focus on core platform offerings rather than direct clinical service provision in all areas.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark Amwell's performance against industry standards. It highlights the company's operation at a large scale and service to major healthcare organizations, but lacks quantitative comparisons.

Related Party Transactions

• Accounts receivable from related parties were $1,239 thousand as of June 30, 2025, and $616 thousand as of December 31, 2024.
• Current deferred revenue from related parties was $147 thousand as of June 30, 2025, and $198 thousand as of December 31, 2024.
• Non-current deferred revenue from related parties was $0 as of June 30, 2025, and $10 thousand as of December 31, 2024.
• Revenue from related parties was $833 thousand for the three months ended June 30, 2025, and $1,265 thousand for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Mixed impact due to improved EBITDA and strategic wins offset by reduced revenue guidance and continued net losses. The 2026 positive cash flow target offers a long-term positive outlook.
• Employees: Strategic transformation initiatives and cost alignment measures may imply potential for future operational adjustments, though no specific workforce changes were announced.
• Customers (Payers & Health Systems): The addition of Florida Blue and the DHA extension indicate continued value proposition and service delivery, reinforcing confidence in the platform.

Next Steps

• Host a conference call on August 5, 2025, at 5 p.m. ET to discuss financial results.
• Continue strategic transformation initiatives.
• Work towards achieving positive cash flow from operations in 2026.

Key Dates

Recommendation

While Amwell demonstrated strong progress in cost alignment and EBITDA improvement, alongside significant strategic client wins, the downward revision of full-year revenue guidance and the projected sequential decline in Q3 revenue raise concerns about top-line growth. The company continues to operate at a net loss and burn cash from operations, although the path to positive cash flow by 2026 is reiterated. The mixed signals suggest a 'hold' recommendation, as the positive operational improvements are offset by revenue challenges, warranting further observation of future quarters' performance and execution on strategic initiatives.

Keywords

Telehealth, Digital Health, Virtual Care, SaaS Healthcare, Amwell, AMWL, Healthcare Platform, Financial Results, Earnings, Q2 2025, Adjusted EBITDA, Revenue Guidance, Florida Blue, Defense Health Agency